Clinical trials: Severe Respiratory Distress
ARDS, Human, COVID
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19.
- Trial name
- COVIPOC (NCT04594668)
- Testing
- Senicapoc
- Where
- 4 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
Septic Shock, Severe Sepsis
Efficacy of Hydrocortisone in Treatment of Severe Sepsis/Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Severe sepsis/septic shock is a serious condition associated with high mortality rate. Hydrocortisone has been recommended as a useful treatment to decrease mortality in hemodynamically unstable septic shock patients, not…
- Conditions
- Septic Shock, Severe Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
- Trial name
- NCT01284452
- Testing
- Hydrocortisone
- Where
- Thailand
- Volunteers
- 197 people
- Sponsor
- Mahidol University
Acute Respiratory Distress Syndrome
Airway Pressure Release Ventilation for Moderate-to-severe Acute Respiratory Distress Syndrome
This study will examine the feasibility of a large clinical trial investigating the effectiveness of airway pressure release ventilation and low tidal volume ventilation for patients with moderate-to-severe acute respiratory…
- Trial name
- EARL (NCT04156438)
- Testing
- Low tidal volume ventilation, Airway pressure release ventilation
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Saskatchewan Health Authority - Regina Area
Acute Respiratory Distress Syndrome
Effect of Mechanical Ventilation Strategy on Lung Injury in Patients With Less Severe Acute Respiratory Distress Syndrome: Targeted on RAGE
During the past two decades, there current concept has evolved significantly that ventilator-induced lung injury (VILI) may not only impose a direct mechanical stress and subsequent injury to the lungs, but may also induce local…
- Trial name
- NCT01301872
- Testing
- check biomarker :RAGE
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Moderate Acute Respiratory Distress Syndrome
Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS
Pathophysiological, experimental and clinical data suggest that an '"ultraprotective" mechanical ventilation strategy may further reduce VILI and ARDS-associated morbidity and mortality.
- Trial name
- SUPERNOVA (NCT02282657)
- Testing
- ECCO2R will be initiated during the 2-hour run-in time, Neuromuscular blocking agents (NMBA), Ventilation
- Where
- Belgium
- Volunteers
- 95 people
- Sponsor
- European Society of Intensive Care Medicine
Pulmonary and Renal State
Acute and Chronic Pulmonary and Renal Complications Following Contracting Severe Respiratory Distress Syndrome Coronavirus-19
Tracking post- corona virus infection pulmonary and renal complications
- Trial name
- NCT04827017
- Testing
- follow up
- Volunteers
- 1,000 people
- Sponsor
- Minia University
Coronavirus, Respiratory Distress Syndrome
LIBERATE Trial in COVID-19
The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
- Conditions
- Coronavirus, Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- LIBERATE (NCT04334629)
- Testing
- Ibuprofen
- Where
- United Kingdom
- Sponsor
- King's College London
ARDS, Human, Sepsis, Severe
The Effect pf Goal-directed De-escalation in ARDS on Organ Function and Mortality
Objective: To compare two de-escalation strategies guided by either extravascular lung water or global end-diastolic volume-oriented algorithms in patients with sepsis and ARDS. Design: A prospective randomized study.
- Trial name
- NCT04508296
- Testing
- Goal directed de-escalation therapy
- Where
- Russia
- Volunteers
- 46 people
- Sponsor
- Northern State Medical University
ARDS (Acute Respiratory Distress Syndrome)
Comparative Study Between Airway Pressure Release Ventilation and Pressure Regulated Volume Control (PRVC) in Protective Lung Strategy as a Recruitment Maneuver for Severe ARDS Mechanically Ventilated Patients Using Lung Ultrasound Score
The aim of this study is to elaborate on the effectiveness of recruitment maneuver by airway pressure release ventilation (APRV) as an open lung ventilatory strategy in comparison with PRVC mode in lung protective strategy…
- Trial name
- NCT07231107
- Testing
- Lung ultrasound
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Acute Respiratory Distress Syndrome, Covid19
Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19
Acute myocardial injury has been a finding of variable frequency among patients diagnosed with COVID-19. It is now recognized that cTnI levels are strongly associated with increased mortality.
- Conditions
- Acute Respiratory Distress Syndrome, Covid19, Myocardial Injury
- Trial name
- PREMIER (NCT04760821)
- Testing
- Trimetazidine
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Ministry of Health, Brazil
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients.
- Trial name
- I-SPY_COVID (NCT04488081)
- Testing
- Remdesivir, Imatinib Mesylate, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Acute Respiratory Distress Syndrome (ARDS)
Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia
This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality.
- Trial name
- APRiCE (NCT02167698)
- Testing
- Airway Pressure Release Ventilation (APRV), Low-tidal volume ventilation, Methylprednisolone
- Where
- India
- Volunteers
- 52 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hypoxia, Respiratory Acidosis
FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC) Feasibility Study
A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill…
- Conditions
- Hypoxia, Respiratory Acidosis, Moderate/Severe Respiratory Distress
- Trial name
- FIRST-ABC (NCT02612415)
- Testing
- Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula, Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure
- Where
- 3 sites in United Kingdom
- Volunteers
- 121 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Covid19, ARDS
Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome
Non-invasive ventilation can allow to avoid intubation and improve outcomes in moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS).
- Trial name
- COVID-NIV (NCT04667923)
- Testing
- Respiratory monitoring, Respiratory muscles ultrasound, Electro impedance tomography
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is the main clinical presentation of SARS-CoV-2 (Covid-19) infected patients admitted in Intensive Care Unit (ICU).
- Trial name
- SONIC-19 (NCT04725084)
- Testing
- Use of High Flow Nasal Cannula alone, Use of Non-invasive Ventilation, Use of Continuous Positive Airway Pressure
- Where
- 4 sites in France
- Volunteers
- 355 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
COVID-19
COVID-19 : Study of INFLAmmasome and PLAtelets Functions
COVID-19 pandemic is a severe viral sepsis characterized by the occurrence of Acute respiratory distress syndrome (ARDS) whose pathophysiology is little described
- Trial name
- CO-QUETTES (NCT04397822)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 61 people
- Sponsor
- University Hospital, Toulouse
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.